<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148134">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02099487</url>
  </required_header>
  <id_info>
    <org_study_id>1139</org_study_id>
    <nct_id>NCT02099487</nct_id>
  </id_info>
  <brief_title>Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma</brief_title>
  <official_title>Hypofractionated Imrt (Vmat-Ra) With Temozolomide For Elderly Patients, Unsuitable For Surgery With Newly Diagnosed High Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <authority>Italy: National Bioethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of IMRT using VMAT rapidarc approach, followed by adjuvant temozolomide
      on survival and quality of life in elderly, poor performance status  patients with newly
      diagnosed  HGG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators designed  this study  with the aim  to assess the effect of IMRT using VMAT
      rapidarc approach, followed by adjuvant temozolomide on survival and quality of life in
      elderly, poor performance status  patients with newly diagnosed  HGG.  The potential
      advantage of this approach is deliver a more selective irradiation to tumor's target with
      reducing the dose to normal brain and to allow the delivery of a higher dose, optimizing the
      therapeutic window.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall Survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Toxicity</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of hematologic and non hematologic severe toxicities (grade III/ IV) will evaluate using NCI-CTCA scale. Late toxicity will evaluate using CTCA 4.2</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Quality of Life</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate safety and feasibility of hypofractionated Intensity Modulated Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>hypofractionated IMRT</description>
    <arm_group_label>Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged ≥ 70 years

          -  Karnosky performance status (KPS) ≤60

          -  Histologically confirmed  HGG after tumor biopsy

               -  GBM

               -  Anaplastic Astrocytoma

               -  Anaplastic Oligoastrocytoma

               -  Anaplastic Oligodendroglioma without IDH1 mutation and no codeletion 1p19q

          -  Estimated survival  ≥ 3 months.

          -  Normal liver, Kidney and bone marrow function

          -  Written informed consent

        Exclusion criteria:

          -  Prior radiation therapy

          -  Other primary cancer

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piera Navarria, MD</last_name>
    <role>Study Director</role>
    <affiliation>Humanitas Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierina Navarria, M.D.</last_name>
    <phone>+3082247458</phone>
    <email>piera.navarria@humanitas.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICH Humanitas Cancer Center</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <zip>20090</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piera Navarria, M.D.</last_name>
      <phone>+390282247458</phone>
      <email>piera.navarria@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Marta Scorsetti, Director</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>January 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>HGG</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
